医学
沙发评分
器官功能障碍
重症监护室
重症监护
多器官功能障碍综合征
呼吸衰竭
队列研究
前瞻性队列研究
内科学
败血症
入射(几何)
重症监护医学
物理
光学
作者
Jean–Louis Vincent,Andre Geraldo Casagrande de Mendonça,Francis Cantraine,Rui P. Moreno,Jukka Takala,Suter Pm,C. L. Sprung,Francis Colardyn,S Blecher
出处
期刊:Critical Care Medicine
[Ovid Technologies (Wolters Kluwer)]
日期:1998-11-01
卷期号:26 (11): 1793-1800
被引量:2945
标识
DOI:10.1097/00003246-199811000-00016
摘要
To evaluate the use of the Sequential Organ Failure Assessment (SOFA) score in assessing the incidence and severity of organ dysfunction in critically ill patients.Prospective, multicenter study.Forty intensive care units (ICUs) in 16 countries.Patients admitted to the ICU in May 1995 (n = 1,449), excluding patients who underwent uncomplicated elective surgery with an ICU length of stay <48 hrs.None.The main outcome measures included incidence of dysfunction/failure of different organs and the relationship of this dysfunction with outcome. In this cohort of patients, the median length of ICU stay was 5 days, and the ICU mortality rate was 22%. Multiple organ dysfunction and high SOFA scores for any individual organ were associated with increased mortality. The presence of infection on admission (28.7% of patients) was associated with higher SOFA scores for each organ. The evaluation of a subgroup of 544 patients who stayed in the ICU for at least 1 wk showed that survivors and nonsurvivors followed a different course. This subgroup had greater respiratory, cardiovascular, and neurologic scores than the other patients. In this subgroup, the total SOFA score increased in 44% of the nonsurvivors but in only 20% of the survivors (p < .001). Conversely, the total SOFA score decreased in 33% of the survivors compared with 21% of the nonsurvivors (p < .001).The SOFA score is a simple, but effective method to describe organ dysfunction/failure in critically ill patients. Regular, repeated scoring enables patient condition and disease development to be monitored and better understood. The SOFA score may enable comparison between patients that would benefit clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI